Abbott posts Q4 topline miss as Nutrition unit contracts (ABT)
Abbott Laboratories (ABT) lost ~5% in the premarket on Thursday after the MedTech giant reported lower-than-expected revenue for Q4 2025 following underperformance in its Nutrition segment. The company recorded $11.5B in net sales for the quarter with ~4% YoY growth, missing the $11.8B projected by ...